Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions (Dietary Supple)
19. juni 2026 opdateret af: Sihame Lkhoyaali, Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)
Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software
The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies.
The main questions it aims to answer :
- What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile?
- Are there any potential drug interactions between dietary supplements and anticancer medications?
Participants will:
- Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics.
- Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication).
- Report any perceived adverse effects related to dietary supplement use to assess tolerance.
- Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Undersøgelsestype
Observationel
Tilmelding (Anslået)
1000
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Sihame Lkhoyaali, Professor of Medical Oncology
- Telefonnummer: +212 668-270035
- E-mail: slkhoyaali@cm6.ma
Undersøgelse Kontakt Backup
- Navn: Badiaa Batlamous
- Telefonnummer: +212 693572066
Studiesteder
-
-
-
Rabat, Marokko
- Rekruttering
- Institut National d'Oncologie
-
Kontakt:
- Sihame Lkhoyaali, Professor of Medical Oncology
- Telefonnummer: +212 668-270035
- E-mail: slkhoyaali@cm6.ma
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Adult patients diagnosed with cancer and receiving medical anticancer treatment (chemotherapy, hormone therapy, immunotherapy, or targeted therapy) at the study site.
Participants will be assessed for dietary supplement use, tolerance, and potential interactions between dietary supplements and anticancer medications.
Beskrivelse
Inclusion Criteria:
- Patients diagnosed with cancer and receiving medical anticancer treatment, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies.
- Current or recent use of one or more dietary supplements (e.g., vitamins, minerals, herbal products, or other nutritional supplements).
- Adult patients : >=18
Exclusion Criteria:
- Patients unable to complete the study questionnaire because of cognitive impairment or a deteriorated health condition.
- Failure or refusal to provide written informed consent.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Cancer Patients Using Dietary Supplements
|
Participants will complete a structured face-to-face questionnaire on dietary supplement use, reasons for Use, frequency and duration of use, perceived adverse effects, and concomitant anticancer treatments.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Prevalence of Dietary Supplement Use and Tolerance
Tidsramme: At enrollment
|
Assessment of the prevalence of dietary supplement use among cancer patients and evaluation of adverse effects associated with dietary supplement consumption.
|
At enrollment
|
|
Potential Drug-Supplement Interactions
Tidsramme: At enrollment or single study visit
|
Assessment of potential interactions between dietary supplements and anticancer medications
|
At enrollment or single study visit
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Potential Drug-Supplement Interactions Assessed by Artificial Intelligence
Tidsramme: At enrollment or Single study visit
|
Assessment of potential interactions between dietary supplements and anticancer treatments using Hedrine software.
|
At enrollment or Single study visit
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. juni 2025
Primær færdiggørelse (Anslået)
1. juni 2027
Studieafslutning (Anslået)
31. december 2027
Datoer for studieregistrering
Først indsendt
19. juni 2026
Først indsendt, der opfyldte QC-kriterier
19. juni 2026
Først opslået (Faktiske)
26. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
26. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
19. juni 2026
Sidst verificeret
1. juni 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ONCOSUPP-2026-08
- CE/UM6SS/18/2025 (Anden identifikator: Ethics Committee of Mohammed VI University of Health and Science (UM6SS), Casablanca, Morocco)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .